Published in Drug Week, December 17th, 2004
Under the terms of the agreement, Lonza has agreed to perform numerous process development related services and manufacture Aurexis for future clinical trials using its proprietary glutamine synthetase expression system.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.